Program Information

 

Join your colleagues at AGS19 for a Live Educational Product Theater entitled,
Advances in Seasonal Influenza Vaccines: Making the Case for Adjuvanted and Cell-Based Vaccines
sponsored by Seqirus USA Inc.

Product Theater Overview:
Seasonal influenza severity varies from season to season. It also carries significant clinical burden, especially in the older population who tend to have more chronic conditions and a declined immune system compared to healthier younger individuals. In recent years, it has been estimated that between about 70% and 90% of seasonal influenza-related deaths within the United States have occurred in people 65 years and older and between 50% and 70% of seasonal flu-related hospitalizations have occurred in the same age group.1

The best form of influenza prevention lies with annual vaccination strategies. However, the extent to which influenza vaccines work can differ with each season. Factors that can influence this are: the characteristics of the person being vaccinated (such as age and health) and the similarity or ‘match’ between the virus strains contained within the influenza vaccine to that circulating in the wild.

With the waning immune system in the elderly, along with the potential mismatch between the vaccine selected strains versus circulating strains, this population group does not always have a good immune response to an influenza vaccine. As a result, there is a need for different influenza vaccines specifically designed to address these challenges.

In this presentation, we will be focusing on the clinical burden of seasonal influenza in the older population, the unique challenges posed by seasonal influenza that impact vaccine development, and the rationale for alternative influenza vaccine options including adjuvanted and cell-based influenza vaccines for the older population.

The objectives for this program will be to:

  • Describe the clinical burden of seasonal influenza in older adults
  • List the unique challenges posed by seasonal influenza that impact vaccine development
  • Explain the rationale for alternative technologies including adjuvanted and cell-based influenza vaccines for older adults
  • Review the clinical data for Adjuvanted Seasonal Influenza Vaccine and MDCK (Madin Darby Canine Kidney) Cell-Based Seasonal Influenza Vaccine
 

American Geriatrics Society (AGS) 2019 Annual Scientific Meeting

Friday, May 3, 2019
12:45 PM – 1:45 PM
Oregon Convention Center
Product Theater - Exhibit Halls C & D
777 NE Martin Luther King Jr Blvd
Portland, OR 97232



OR
Call toll-free 1-888-914-3679

Lauren B. Angelo, PharmD, MBA
Associate Professor and Assistant Dean for Academic Affairs
Rosalind Franklin University of Medicine and Science
North Chicago, Illinois

Held during the American Geriatrics Society 2019 Annual Scientific Meeting.



This presentation may include information on vaccines, drugs, biologics or devices, or use of vaccines, drugs, biologics or devices that may not have been approved by the Food and Drug Administration (FDA) or have been approved by the FDA for specific uses only.

Seqirus is committed to the free exchange and advancement of medical and scientific education. Inclusion of any presentation in this program, including presentation of off-label uses, does not imply an endorsement by Seqirus of the uses, products, or techniques presented.

1. People 65 years and older and influenza. Centers for Disease Control and Prevention Website. https://www.cdc.gov/flu/about/disease/65over.htm. Updated February 12, 2019. Accessed March 14, 2019.